How to Obtain Selective Androgen Receptor Modulators (SARMs)
Below is a practical guide that explains what SARMs are, why they’re regulated, and the legal path for obtaining them in the United States.
It also highlights the risks of buying or using SARMs without medical oversight.
---
1. What Are SARMs?
SARMs (Selective Androgen Receptor Modulators) are a class of compounds that bind to androgen receptors but act more selectively than traditional anabolic steroids.
They were originally developed for therapeutic uses (e.g., muscle wasting, osteoporosis) because they can increase lean body mass with fewer side effects such as prostate enlargement or liver toxicity.
In the market, SARMs are often sold as "research chemicals" or "supplements," but they are not approved by the FDA for any human use.
2. Legal Status
Country Regulatory Status
United States (FDA) Unapproved; classified as a drug, not a supplement. Illegal to market or distribute for human consumption.
European Union (EMA) Not approved; sale for human consumption prohibited.
Canada (Health Canada) Not approved; sale and importation for human use illegal.
Australia (TGA) Unapproved; not available for medical use.
In the US, possessing or selling these substances for human consumption is a federal offense.
Some jurisdictions may allow possession for research purposes with proper licenses.
3.2 Clinical Trial Eligibility and Regulatory Pathways
Investigational New Drug (IND) Application: Before initiating any human trials in the US, an IND must be filed with the FDA detailing preclinical data, manufacturing details, and study protocols.
Good Manufacturing Practice (GMP): The drug must be manufactured under GMP conditions; facilities must meet regulatory standards.
Ethics Approval: Institutional Review Board (IRB) approval is required for each trial site.
3.3 Intellectual Property Considerations
Patentability: Novel uses or combinations may be patentable even if the compound itself is not novel.
Freedom to Operate: Ensure no existing patents cover the intended use; conduct a thorough freedom-to-operate search.
4. Case Study: Translating an Anticancer Compound from Bench to Bedside
Below is a simulated example of how one might progress a promising anticancer compound through development stages, including strategic decisions and potential pitfalls.
Discovery High-throughput screening → Hit identification (e.g., 3‑O‑methyl‑4‑hydroxy‑cinnamic acid) Is the hit selective? Do we have a clear mechanism of action? Early selection of a suboptimal scaffold; ignoring off‑target effects
Lead Optimization SAR studies, medicinal chemistry → Lead with improved potency (IC₅₀ <1 µM), metabolic stability Which functional groups to modify? Does the lead cross the blood–brain barrier? Over-optimizing potency at the expense of ADMET properties; late-stage toxicity
Preclinical Development In vitro ADME, in vivo PK/PD, toxicology (2‑week rat study) Is the compound safe in animals? Are there organ-specific toxicities? Insufficient exposure data leading to underestimation of dose requirements
Clinical Translation Phase I human safety → Phase II efficacy trials Does the drug reach therapeutic concentrations? Do patients respond? Inadequate biomarker selection causing false negatives; high dropout rates
---
4. How "Drug‑like" and "Target‑driven" Parameters Shape Drug Discovery
Parameter Influence on Discovery Process Typical Screening/Optimization Strategies
Molecular weight (MW) ≤ 500 Da Limits structural complexity; improves cell penetration. Use Lipinski’s rule‑of‑five filters during library curation.
LogP 0–5 Balances solubility and permeability. Perform in silico QSAR, optimize polar surface area (PSA).
HBA/HBD count Reduces risk of poor oral absorption. Apply Veber’s rule; minimize HBDs during medicinal chemistry.
Rotatable bonds ≤ 10 Enhances metabolic stability. Use RDKit to count rotatable bonds and enforce thresholds.
Target protein (e.g., kinases) Determines pharmacophore features. Generate 3D structure, identify hinge-binding pocket for docking.
Thermodynamics / Heat of Reaction: `Cantera` (uses NASA polynomials), `RMG` for mechanism generation, or external databases.
Kinetics & Mechanisms: RMG and Cantera provide rate constants and reaction networks.
Use the appropriate library based on whether you need simple stoichiometry, detailed thermodynamic data, or a full kinetic mechanism. For most combustion problems, starting with Cantera is recommended because it integrates both thermodynamics and kinetics for gas-phase reactions. If you require automatic mechanism generation, then RMG can be used in conjunction with Cantera.
